APA WF # 25-15 340B Revisions

TThese rule revisions seek to remove certain high-cost drugs and therapies from the 340B Drug Pricing Program. The 340B program is a federal initiative that allows health care organizations to purchase certain drugs directly from pharmaceutical manufacturers at a discount. The revision creates a 340B Carve Out Drug list, consisting of cell and gene therapies, drugs currently under a value-based agreement, or Brand Preferred Drugs where the cost to the Medicaid program is $500,000 or higher, annually. Drugs on this list would be prohibited from being dispensed or administered to Oklahoma Medicaid Members if purchased at 340B prices.

Please view the draft regulatory text here: APA WF# 25-15 and submit feedback via the comment box.

Circulation Date: 8/27/2025

Tribal Consultation: 9/2/2025

Comment Due Date: 9/16/2025

Board Date: 9/17/2025